The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach

50Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to an infection, remains a major challenge for clinicians and trialists. Despite decades of research and multiple randomized clinical trials, a specific therapeutic for sepsis is not available. The evaluation of therapeutics targeting components of host response anomalies in patients with sepsis has been complicated by the inability to identify those in this very heterogeneous population who are more likely to benefit from a specific intervention. Additionally, multiple and diverse host response aberrations often co-exist in sepsis, and knowledge of which dysregulated biological organ system or pathway drives sepsis-induced pathology in an individual patient is limited, further complicating the development of effective therapies. Here, we discuss the drawbacks of previous attempts to develop sepsis therapeutics and delineate a future wherein interventions will be based on the host response profile of a patient.

Cite

CITATION STYLE

APA

Vincent, J. L., van der Poll, T., & Marshall, J. C. (2022, September 1). The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach. Biomedicines. MDPI. https://doi.org/10.3390/biomedicines10092260

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free